Toyobo Co., Ltd. of Osaka at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option
Manufacturers

Toyobo Co., Ltd.

2-2-8, Dojima-Hama Kita-ku, 530-8230 Osaka
Japan
Telephone +81 6 63483864
Fax +81 6 63483833
naoki_nishio@toyobo.jp

This company is main exhibitor of

Hall map

MEDICA 2019 hall map (Hall 3): stand C33

Fairground map

MEDICA 2019 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.01  Clinical chemistry
  • 03.01.04  Rapid tests in clinical chemistry

Rapid tests in clinical chemistry

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.01  Immuno assay testing

Immuno assay testing

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.02  Diagnostic rapid tests

Diagnostic rapid tests

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.03  Diagnostic tests for cancer

Diagnostic tests for cancer

Our products

Product category: Rapid tests in clinical chemistry

POCube®

Compact Chemiluminescent Autoanalyzer POCube®
POCube® is useful all around the hospital, especially inside emergency wards and hospital rooms, because it is compact and can provide results in just about five minutes. This autoanalyzer is presently measures C-reactive protein. The test items will be increased to cover influenza virus and other clinical items, to make POCube® even more convenient.

More Less

Product category: Immuno assay testing

GENECUBE®

Full Automatic Gene Analyzing System GENECUBE®
GENECUBE® is a genetic testing instrument which can identify pathogens. It is the world's first instrument which can conduct automated genetic testing using biological samples other than blood. GENECUBE® will be used for various applications, including the selection of effective medicines.

More Less

About us

Company details

The category leader, continuing to create new value
that contributes to society in the environment, healthcare,
and high-function product fields.

Toyobo has overcome the crisis of deteriorating performance stemming from the global recession,
and is seeking to regain growth. Over the past year our earnings capacity has steadily recovered,
and now we are shifting our priority to achieving growth.

From “Recovery” to “Growth”
PresidentSeiji Narahara
Toyobo has overcome the crisis of deteriorating performance stemming from the global recession, and is seeking to regain growth. Over the past year our earnings capacity has steadily recovered, and now we are shifting our priority to achieving growth.

In light of the new business environment, Toyobo recently formulated a new medium-term management plan to be implemented through the fiscal year ending March 2014. The vision is for Toyobo to become “the category leader, continuing to create new value that contributes to society in the environment, healthcare, and high-function product fields.” A “category leader” is a business that overwhelmingly dominates in a specific market or field as a result of a company’s unique technologies and expertise. We will expand our strong businesses both in Japan and abroad, and work to generate the next categoryleading businesses. We anticipate 8% annual growth in our specialty businesses, and will continue to manage the textiles and other businesses with an emphasis on asset efficiency. We expect the specialty business fields to account for 75% of sales by fiscal 2014, establishing a high-earning business portfolio.

More Less